What it sells
Nomic is doing for proteins what Illumina has done for DNA
Business model breakdown
Buyer: who owns the budget?
UnverifiedPharma/biotech R&D and academic labs (150+ institutions supported).
Trigger: what makes them buy now?
Need affordable, high-throughput protein profiling at scale for discovery and translational studies.
Workflow: what inputs become what output?
Customer ships samples to Nomic service, nELISA profiles 1,000 proteins (Omni 1000) or custom panels, data returned through a portal.
Economics: what it saves and how it charges
Fee-for-service assay profiling; markets "the $50 proteome" (1,000 proteins quantified per sample).
Distribution: how it reaches customers
Contact/Start now sales, partnerships (Broad Clinical Labs, Sanger), grants and publications.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2020 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.